FrancophonIA/ELRC3.0 huggingface dataset:
English: The product is ovicidal for 3 weeks after administration.
Estonian: Veterinaarravim tapab kirbumune kuni 3 nädalat pärast manustamist.
English: When replacing another heartworm preventive veterinary medicinal product in a heartworm disease prevention programme, the first dose of the veterinary medicinal product must be given within a month of the last dose of the former medication.
Estonian: Ühe südameusstõve profülaktilise veterinaarravimi asendamisel teisega tuleks esimene annus manustada ühe kuu jooksul pärast eelmise ravimi viimase annuse manustamist.
English: Marketing authorisation holder and manufacturer responsible for batch release: Chanelle Pharmaceuticals Manufacturing Ltd, Loughrea,
Estonian: Müügiloa hoidja ja partii vabastamise eest vastutav tootja: Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, Co. Galway, Ireland
English: Chanhold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg selamectin
Estonian: Chanhold 15 mg täpilahus kassidele ja koertele ≤ 2,5 kg selamektiin
English: Dogs weighing 2.6-5.0 kg.
Estonian: Kassid kehamassiga 7,6-10,0 kg.
English: This ensures that fleas infesting the animal are killed, no viable flea eggs are produced by these fleas, and larvae (found only in the environment) are also killed.
Estonian: See kindlustab loomal ja teda ümbritsevas keskkonnas parasiteerivate kirpude hukkumise, eluvõimeliste munade tootmise lõppemise ja (ainult keskkonnas leiduvad) larvid hukkuvad.
English: Chanhold 45 mg spot-on solution for cats 2.6-7.5 kg Chanhold 60 mg spot-on solution for cats 7.6-10.0 kg selamectin
Estonian: Chanhold 45 mg täpilahus kassidele kehamassiga 2,6-7,5 kg Chanhold 60 mg täpilahus kassidele kehamassiga 7,6-10,0 kg selamektiin
English: 6% w/v solution Selamectin 15 mg
Estonian: 6% lahus selamektiin 15 mg
English: 6% w/v solution Selamectin 45 mg
Estonian: 6% lahus selamektiin 45 mg
English: Cats and dogs weighing 2.5 kg or less
Estonian: Kassid ja koerad kehamassiga kuni 2,5 kg.
English: Treatment of pregnant and lactating animals to prevent flea infestations in puppies and kittens:
Estonian: Tiinete ja imetavate loomade ravi kutsikate ning kassipoegade kirbuinfestatsiooni profülaktikaks
English: Chanhold 30 mg for dogs
Estonian: Chanhold 30 mg kassidele ja koertele
English: Chanhold 45 mg for cats
Estonian: Chanhold 45 mg kassidele ja koertele
English: Dogs weighing 5.1-10.0 kg.
Estonian: Kassid kehamassiga 2,5-7,5 kg.
English: Cats and dogs weighing 2.5 kg or less (Chanhold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg) Dogs weighing 2.6 kg-5.0 kg (Chanhold 30 mg spot-on solution for dogs 2.6-5.0 kg) Cats weighing 2.6 kg-7.5 kg (Chanhold 45 mg spot-on solution for cats 2.6-7.5 kg) Cats weighing 7.6 kg-10.0 kg (Chanhold 60 mg spot-on solution for cats 7.6-10.0 kg) Dogs weighing 5.1 kg-10.0 kg (Chanhold 60 mg spot-on solution for dogs 5.1-10.0 kg) Dogs weighing 10.1 kg-20.0 kg (Chanhold 120 mg spot-on solution for dogs 10.1-20.0 kg) Dogs weighing 20.1 kg-40.0kg (Chanhold 240 mg spot-on solution for dogs 20.1-40.0 kg) Dogs weighing 40.1 kg-60.0 kg (Chanhold 360 mg spot-on solution for dogs 40.1-60.0 kg)
Estonian: Kassid ja koerad kehamassiga kuni 2,5 kg (Chanhold 15 mg täpilahus kassidele ja koertele ≤ 2,5 kg) Koerad kehamassiga 2,5-5,0 kg (Chanhold 30 mg täpilahus koertele 2,5-5,0 kg) Kassid kehamassiga 2,6-7,5 kg (Chanhold 45 mg täpilahus kassidele 2,6-7,5 kg) Kassid kehamassiga 7,6-10,0 kg (Chanhold 60 mg täpilahus kassidele 7,6-10,0 kg) Koerad kehamassiga 5,1-10,0 kg (Chanhold 60 mg täpilahus koertele 5,1-10,0 kg) Koerad kehamassiga 10,1-20,0 kg (Chanhold 120 mg täpilahus koertele 10,1-20,0 kg) Koerad kehamassiga 20,1-40 kg (Chanhold 240 mg täpilahus koertele 20,1-40 kg) Koerad kehamassiga 40,1-60,0 kg (Chanhold 360 mg täpilahus koertele 40,1-60,0 kg)
English: Chanhold 60 mg for dogs
Estonian: Chanhold 60 mg kassidele ja koertele
English: • Treatment of adult roundworms (Toxocara cati)
Estonian: • Ümarusside (Toxocara cati) täiskasvanud vormide põhjustatud parasitooside ravi
English: Pregnancy: Can be used in pregnant cats and dogs.
Estonian: Laktatsioon Võib kasutada imetavatele kassidele ja koertele.
English: 12% w/v solution Selamectin 60 mg
Estonian: 12% lahus selamektiin 60 mg
English: 6% w/v solution Selamectin 60 mg
Estonian: 6% lahus selamektiin 60 mg
English: 12% w/v solution Selamectin 30 mg
Estonian: 12% lahus selamektiin 30 mg
English: This is as a result of the adulticidal, larvicidal and ovicidal properties of the product.
Estonian: Selle veterinaarravimi omaduste tõttu hukkuvad kirpude täiskasvanud vormid, munad ja larvid.
English: Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestations in the litter up to seven weeks of age.
Estonian: Tiinete ja imetavate loomade igakuine ravi vähendab kirbupopulatsiooni, soodustades kirbuinvasiooni profülaktikat pesakonnas kuni seitsmenda elunädalani.
English: Chanhold 120 mg for dogs
Estonian: Chanhold 120 mg kassidele ja koertele 12% lahus selamektiin 120 mg
English: Veterinary medicinal product subject to prescription.
Estonian: Et vähendada veterinaarravimi äralakkumist, on tähtis manustada ravimit juhendi kohaselt.
English: Chanhold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg Chanhold 30 mg spot-on solution for dogs 2.6-5.0 kg Chanhold 45 mg spot-on solution for cats 2.6-7.5 kg Chanhold 60 mg spot-on solution for cats 7.6-10.0 kg Chanhold 60 mg spot-on solution for dogs 5.1-10.0 kg Chanhold 120 mg spot-on solution for dogs 10.1-20.0 kg Chanhold 240 mg spot-on solution for dogs 20.1-40.0 kg Chanhold 360 mg spot-on solution for dogs 40.1-60.0 kg
Estonian: Chanhold 15 mg täpilahus kassidele ja koertele ≤ 2,5 kg Chanhold 30 mg täpilahus koertele 2,6-5,0 kg Chanhold 45 mg täpilahus kassidele 2,6-7,5 kg Chanhold 60 mg täpilahus kassidele 7,6-10,0 kg Chanhold 60 mg täpilahus koertele 7,6-10,0 kg Chanhold 120 mg täpilahus koertele 10,1-20,0 kg Chanhold 240 mg täpilahus koertele 20,0-40,0 kg Chanhold 360 mg täpilahus koertele 40,1-60,0 kg
English: Chanhold 30 mg spot-on solution for dogs 2.6-5.0 kg Chanhold 60 mg spot-on solution for dogs 5.1-10.0 kg Chanhold 120 mg spot-on solution for dogs 10.1-20.0 kg Chanhold 240 mg spot-on solution for dogs 20.1-40.0 kg Chanhold 360 mg spot-on solution for dogs 40.1-60.0 kg selamectin
Estonian: Chanhold 30 mg täpilahus koertele 2,6-5,0 kg Chanhold 60 mg täpilahus koertele 7,6-10,0 kg Chanhold 120 mg täpilahus koertele 10,1-20,0 kg Chanhold 240 mg täpilahus koertele 20,0-40,0 kg Chanhold 360 mg täpilahus koertele 40,1-60,0 kg selamektiin
English: Chanhold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg Chanhold 30 mg spot-on solution for dogs 2.6-5.0 kg Chanhold 45 mg spot-on solution for cats 2.6-7.5 kg Chanhold 60 mg spot-on solution for cats 7.6-10.0 kg Chanhold 60 mg spot-on solution for dogs 5.1-10.0 kg Chanhold 120 mg spot-on solution for dogs 10.1-20.0 kg Chanhold 240 mg spot-on solution for dogs 20.1-40.0 kg Chanhold 360 mg spot-on solution for dogs 40.1-60.0 kg selamectin
Estonian: Chanhold 15 mg täpilahus kassidele ja koertele ≤ 2,5 kg Chanhold 30 mg täpilahus koertele 2,6-5,0 kg Chanhold 45 mg täpilahus kassidele 2,6-7,5 kg Chanhold 60 mg täpilahus kassidele 7,6-10,0 kg Chanhold 60 mg täpilahus koertele 7,6-10,0 kg Chanhold 120 mg täpilahus koertele 10,1-20,0 kg Chanhold 240 mg täpilahus koertele 20,0-40,0 kg Chanhold 360 mg täpilahus koertele 40,1-60,0 kg selamektiin
English: Chanhold 360 mg for dogs
Estonian: Chanhold 360 mg kassidele ja koertele 12% lahus selamektiin 360 mg
English: It is important to apply the dose as indicated to minimise the quantity that the animal can lick off.
Estonian: Et vähendada preparaadi ära lakkumist, on tähtis manustada ravimit vastavalt juhendile.
English: Chanelle Pharmaceuticals Manufacturing Ltd, Loughrea,
Estonian: Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, Co. Galway, Ireland
English: Selamectin has adulticidal, ovicidal and larvicidal activity against fleas.
Estonian: Selamektiin toimib täiskasvanud kirpudesse, kirbuvastsetesse ja munadesse.
English: Chanhold 240 mg for dogs
Estonian: Chanhold 240 mg kassidele ja koertele 12% lahus selamektiin 240 mg
English: Animals may be bathed 2 hours after treatment without loss of efficacy.
Estonian: Loomade pesemine kaks või enam tundi pärast veterinaarravimi manustamist ei vähenda efektiivsust.
English: The full EPAR for Pioglitazone Teva Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Pioglitazone Teva Pharma kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The recommended starting dose of Pioglitazone Teva Pharma is 15 or 30 mg once a day.
Estonian: Pioglitazone Teva Pharma soovitatav algannus on 15 või 30 mg üks kord ööpäevas.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pioglitazone Teva Pharma on 26 March 2012.
Estonian: Euroopa Komisjon andis Pioglitazone Teva Pharma müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. märtsil 2012.
English: Treatment with Pioglitazone Teva Pharma should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Estonian: Pioglitazone Teva Pharma ravivastus tuleb kolme kuni kuue kuu möödudes läbi vaadata ning lõpetada ravi patsientidel, kes ei saa ravist piisavalt kasu.
English: The active substance in Pioglitazone Teva Pharma, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Estonian: Pioglitazone Teva Pharma toimeaine pioglitasoon suurendab rakkude (rasva-, lihas- ja maksarakud) tundlikkust insuliini suhtes, mis tähendab, et organism kasutab paremini enda toodetavat insuliini.
English: Pioglitazone Teva Pharma can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Estonian: Pioglitazone Teva Pharmat tohib kasutada ka koos insuliiniga patsientidel, kellele üksnes insuliini manustamine ei mõju rahuldavalt ja kes ei saa kasutada metformiini.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pioglitazone Teva Pharma.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Pioglitazone Teva Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pioglitazone Teva Pharma ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Pioglitazone Teva Pharma is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Estonian: Pioglitazone Teva Pharmat kasutatakse eelkõige ülekaaluliste täiskasvanud (vähemalt 18-aastaste) patsientide II tüüpi diabeedi (suhkurtõve) raviks.
English: Because Pioglitazone Teva Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pioglitazone Teva Pharma on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Committee recommended that Pioglitazone Teva Pharma be given marketing authorisation.
Estonian: Komitee soovitas anda Pioglitazone Teva Pharma müügiloa.
English: Because Pioglitazone Teva Pharma is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Estonian: Et Pioglitazone Teva Pharma on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati ravimi bioekvivalentsust võrdlusravimiga Actos.
English: This means that Pioglitazone Teva Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
Estonian: See tähendab, et Pioglitazone Teva Pharma on sarnane võrdlusravimiga Actos, millel juba on Euroopa Liidus müügiluba.
English: The CHMP concluded that, in accordance with EU requirements, Pioglitazone Teva Pharma has been shown to have comparable quality and to be bioequivalent to Actos.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pioglitazone Teva Pharma võrdväärne kvaliteet ja bioekvivalentsus ravimiga Actos.
English: Pioglitazone Teva Pharma is a ‘generic medicine'.
Estonian: Pioglitazone Teva Pharma on geneeriline ravim.
English: This is a summary of the European public assessment report (EPAR) for Pioglitazone Teva Pharma.
Estonian: See on ravimi Pioglitazone Teva Pharma Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Pioglitazone Teva Pharma
Estonian: Muu teave Pioglitazone Teva Pharma kohta
English: Pioglitazone Teva Pharma should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease).
Estonian: Pioglitazone Teva Pharmat ei tohi kasutada patsiendid, kes saavad dialüüsi (teatud verepuhastustehnika neeruhaiguste korral).
English: Pioglitazone Teva Pharma is a medicine that contains the active substance pioglitazone.
Estonian: Pioglitazone Teva Pharma on ravim, mis sisaldab toimeainena pioglitasooni.
English: Pioglitazone Teva Pharma is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Estonian: Pioglitazone Teva Pharmat kasutatakse ainsa ravimina patsientidel, kellele ei sobi metformiin (samuti diabeediravim).
English: Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Pioglitazone Teva Pharma kasulikkus sellega kaasnevad riskid.
English: What is Pioglitazone Teva Pharma?
Estonian: Mis on Pioglitazone Teva Pharma?
English: Why has Pioglitazone Teva Pharma been approved?
Estonian: Miks Pioglitazone Teva Pharma heaks kiideti?
English: How has Pioglitazone Teva Pharma been studied?
Estonian: Kuidas Pioglitazone Teva Pharmat uuriti?
English: How does Pioglitazone Teva Pharma work?
Estonian: Kuidas Pioglitazone Teva Pharma toimib?
English: What are the benefits and risks of Pioglitazone Teva Pharma?
Estonian: Milles seisneb Pioglitazone Teva Pharma kasulikkus ja mis riskid Pioglitazone Teva Pharmaga kaasnevad?
English: What is Pioglitazone Teva Pharma used for?
Estonian: Milleks Pioglitazone Teva Pharmat kasutatakse?
English: How is Pioglitazone Teva Pharma used?
Estonian: Kuidas Pioglitazone Teva Pharmat kasutatakse?
English: The European Commission issued an EU-wide legally binding decision on 28 November 2014.
Estonian: Euroopa Komisjon tegi kogu Euroopa Liidus õiguslikult siduva otsuse 28. novembril 2014.
English: The medicine is currently marketed in the following Member States of the EU: Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Luxembourg, Malta, Netherlands, Poland, Portugal, Spain, Sweden and United Kingdom, as well as in Iceland and Norway.
Estonian: Ravimit turustatakse praegu järgmistes Euroopa Liidu liikmesriikides: Austrias, Belgias, Hispaanias, Iirimaal, Itaalias, Kreekas, Küproses, Luksemburgis, Lätis, Madalmaades, Maltas, Poolas, Portugalis, Prantsusmaal, Rootsis, Saksamaal, Soomes, Taanis, Tšehhi Vabariigis ja Ühendkuningriigis ning Islandil ja Norras.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28 November 2014
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28.
English: What is EMLA cream?
Estonian: Mis on EMLA kreem?
English: The areas harmonised include:
Estonian: Ühtlustamist vajavad punktid on muu hulgas järgmised.
English: The company that markets these medicines is Astra Zeneca.
Estonian: Ravimit turustab Astra Zeneca.
English: Why was EMLA cream reviewed?
Estonian: Miks EMLA kreemi kohta esitatud taotlus läbi vaadati?
English: The CHMP also harmonised other sections of the SmPC including sections 4.4 (special warning and precautions for use), 4.6 (fertility, pregnancy and lactation) and 4.8 (side effects).
Estonian: Inimravimite komitee ühtlustas ka ravimi omaduste kokkuvõtte muud jaotised, sh jaotised 4.4 (erihoiatused ja ettevaatusabinõud kasutamisel), 4.6 (fertiilsus, rasedus ja imetamine) ning 4.8 (kõrvaltoimed).
English: Having harmonised the indications, the CHMP also harmonised recommendations on the doses and the duration of application of EMLA cream before different medical or surgical procedures in children, adolescents or adults.
Estonian: Pärast näidustuste ühtlustamist ühtlustas inimravimite komitee ka soovitusi annuste ja EMLA kreemi kasutamise kestuse kohta enne erinevaid meditsiinilisi või kirurgilisi protseduure lastel, noorukitel või täiskasvanutel.
English: EMLA cream has been nationally authorised in EU Member States since 1984.
Estonian: EMLA kreem on Euroopa Liidu liikmesriikides olnud riiklike menetluste kaudu heaks kiidetud alates 1984. aastast.
English: EMEA/H/A-30/1388
Estonian: november 2014 EMA/749922/2014 EMEA/H/A-30/1388
English: EMLA cream is authorised in the EU via national procedures.
Estonian: EMLA kreem on Euroopa Liidus heaks kiidetud riiklike menetluste kaudu.
English: In addition, information has been included to explain that studies did not show that EMLA cream is effective at providing adequate pain relief for circumcision (surgical removal of the foreskin).
Estonian: Lisati ka teave, mis selgitab, et uuringud ei ole tõestanud EMLA kreemi piisavat efektiivsust valu leevendamisel ümberlõikamise (eesnaha kirurgiline eemaldamine) korral.
English: After reviewing the available data supporting the medicine's use, the CHMP agreed that EMLA cream can be used for the following:
Estonian: Ravimi kasutamist toetavate andmete läbivaatamise järel nõustus inimravimite komitee, et EMLA kreemi tohib kasutada järgmistel näidustustel:
English: On 25 September 2014, the European Medicines Agency completed a review of EMLA cream.
Estonian: 25. septembril 2014 lõpetas Euroopa Ravimiamet EMLA kreemi kohta tehtud taotluse läbivaatamise.
English: EMLA cream is a topical (skin) cream that contains the active substances lidocaine and prilocaine.
Estonian: EMLA kreem on paikseks kasutamiseks (nahal) mõeldud kreem, mis sisaldab toimeainena lidokaiini ja prilokaiini.
English: In view of this, on 11 October 2013 the German medicines regulatory agency referred the matter to the CHMP in order to harmonise the marketing authorisations for EMLA cream in the EU.
Estonian: Seepärast tegi Saksamaa ravimiamet 11. oktoobril 2013 inimravimite komiteele esildise, et ühtlustada EMLA kreemi müügiload Euroopa Liidus.
English: The CHMP agreed that hypersensitivity (allergy) to lidocaine and/or prilocaine or similar local anaesthetics or to any other ingredients in EMLA cream should be the only contraindication.
Estonian: Inimravimite komitee nõustus, et ainus vastunäidustus peaks olema ülitundlikkus (allergia) lidokaiini ja/või prilokaiini või sarnaste lokaalanesteetikumide või EMLA kreemi muude koostisosade suhtes.
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Estonian: Esitatud andmete hindamise ja komitees toimunud teadusliku arutelu põhjal jõudis inimravimite komitee järeldusele, et ravimi omaduste kokkuvõtted, märgistus ja pakendi infolehed tuleb Euroopa Liidus ühtlustada.
English: It is used as a local anaesthetic to prevent pain during medical or superficial surgical procedures.
Estonian: Seda kasutatakse lokaalanesteetikumina meditsiinilistes või pindmistes kirurgilistes protseduurides valu ennetamiseks.
English: • topical anaesthesia of the skin in adults and children;
Estonian: • naha paikne anesteesia täiskasvanutel ja lastel;
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for EMLA cream in the European Union (EU).
Estonian: Inimravimite komitee järeldas, et EMLA kreemi määramise teave tuleb Euroopa Liidus ühtlustada.
English: • topical anaesthesia of the genital mucosa in adults and adolescents;
Estonian: • suguelundite limaskesta paikne anesteesia täiskasvanutel ja noorukitel;
English: • topical anaesthesia of leg ulcers in adults only.
Estonian: • jalahaavandite paikne anesteesia ainult täiskasvanutel.
English: This has led to divergences across Member States in the way the medicine can be used, as seen in differences in the SmPCs (Summary of Product Characteristics), labelling and package leaflets in the countries where the medicine is marketed.
Estonian: Seetõttu on ravimi näidustused, ravimi omaduste kokkuvõtted, märgistus ja pakendi infoleht ravimit turustavates liikmesriikides erinevad.
English: This summary was last updated on 18/02/2011.
Estonian: Kokkuvõtte viimane uuendus: 18.02.2011.
English: Dogs can be treated for up to six months.
Estonian: Koerte ravi tohib kesta kuni kuus kuud.
English: The first dose was given two hours before surgery, and treatment was continued for several days.
Estonian: Esimene annus anti kaks tundi enne operatsiooni ja ravi jätkati mitme päeva vältel.
English: A study in dogs (average age 8.8 years old) with chronic osteoarthritis lasted for up to 90 days.
Estonian: Kroonilise osteoartroosiga koertel (keskmine vanus 8,8 aastat) korraldati uuring, mis kestis kuni 90 päeva.
English: It must not be used together with corticosteroids or other NSAIDs.
Estonian: Ravimit ei tohi kasutada ka samal ajal koos kortikosteroidide ega teiste NSAID-ravimitega.
English: It is available as oblong chewable tablets, in three different strengths (8 mg, 30 mg and 80 mg).
Estonian: Seda turustatakse kolmes tugevuses (8 mg, 30 mg ja 80 mg) piklike närimistablettidena.
English: The owner also noted pain-related observations.
Estonian: Ka koerte omanikud märkisid üles valuga seotud nähte.
English: It works mainly by blocking an enzyme called cyclo-oxygenase-2 (COX2).
Estonian: Ravimi toime põhineb peamiselt ensüümi tsüklooksügenaas-2 (COX-2) blokeerimisel.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Cimalgex to Vétoquinol SA on 18/02/2011.
Estonian: Euroopa Komisjon andis 18.02.2011 Cimalgexi müügiloa, mis kehtib kogu Euroopa Liidus, ettevõttele Vétoquinol SA.
English: Cimalgex must not be used in dogs aged less than 10 weeks old, and if the dog is less than 6 months of age careful monitoring by the veterinarian is recommended.
Estonian: Cimalgexi ei tohi kasutada alla 10 nädala vanustel koertel; alla 6-kuustel koertel on soovitatav, et ravi toimub veterinaari hoolika järelevalve all.
English: For longer-term treatment, regular monitoring should be undertaken by the veterinary surgeon.
Estonian: Pikaaegse ravi korral peab koer olema veterinaari regulaarse järelevalve all.
English: Information on the prescription status of this product may be found on the label/outer package.
Estonian: Teave selle kohta, kas toode on retseptiravim, on etiketil/välispakendil.
English: In case of accidental ingestion, medical advice should be sought immediately and the package leaflet or the label shown to the doctor.
Estonian: Juhusliku allaneelamise korral tuleb pöörduda kohe arsti poole ja näidata talle ravimi pakendi infolehte või etiketti.
English: Pain was assessed by the veterinarian (up to 24 hours after surgery and at the end of the follow-up treatment).
Estonian: Koertel esinevat valu hindasid veterinaarid (kuni 24 tunni vältel pärast operatsiooni ja järelravi lõpus).